Investigation of the Prevalence of Hepatopulmonary Syndrome in Cirrhosis Patients Caused by Hepatitis B in Western China

• Conditions: Hepatopulmonary Syndrome

• Registration Number: NCT03435406
• Lead Sponsor: Southwest Hospital, China

Brief Summary

to investigate the prevalence of hepatopulmonary syndrome in cirrhosis patients caused by Hepatitis B in western China

Detailed Description

Hepatopulmonary syndrome (HPS) occurs in approximately 4%-29% of cirrhotic patients and influences mortality. China has 100 million Hepatitis B virus (HBV) carriers and Chronic HBV infection is well-recognized risk factor for cirrhosis.But little is known about the prevalence of HPS in cirrhosis patients caused by HBV in western China. The aim of this study was to investigate the HPS incidence, and the signs, symptoms, arterial blood gas, and BMP9 in the serum of the patients.

Study Timeline

• Study Start: 2017-07-27
• Status Verified: 2018-02
• Study First Submitted: 2018-02-02
• Study First Submitted QC: 2018-02-09
• Last Update Submitted: 2018-02-09
• Study First Posted: 2018-02-19
• Last Update Posted: 2018-02-19
• Primary Completion: 2018-04-01
• Study Completion: 2018-04-01

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 300

Inclusion Criteria

1. Age: 18-80 years old;
2. American association of anesthesiologists(ASA) score: I-III;
3. Ability to comply with research programmes;
4. Voluntary participation in the study;
5. Has the history of HBV infection;
6. No primary cardiopulmonary disease (heart disease, emphysema, pneumonia, asthma, etc.)

Exclusion Criteria

1. Severe heart, lung, kidney disease coexisted;
2. American association of anesthesiologists(ASA) score≥IV; forced expiratory volume at one second (FEV1) or forced vital capacity (FVC) <70%, or FEV1 / FVC <0.70;
3. Mental state could not cooperate
4. Absence of written informed consent.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
transthoracic contrast enhanced echocardiography (CEE)	During the operation	through the ultrasound to evaluate the imagine of cardiac cavity after intravenous injection of agitated saline
arterial blood gas	During the operation	arterial blood gas analysis was performed through the radial artery.
liver palms	During the operation	liver palms was examined by inspection
medical history	During the operation	The medical history was collected through consultation.
oxygen saturation	During the operation	oxygen saturation was examined by pulse oximetry
acropachy	During the operation	acropachy was examined by inspection
spider angioma	During the operation	spider angioma was examined by inspection

Secondary Outcome Measures

Name	Time	Method
micro ribonucleic acid 144 (miR144), micro ribonucleic acid 200 (miR200) in the patients with and without HPS	4 to 6 months after the study completion	the content and expression of BMP9 were determined by polymerase chain reaction (PCR)
the content of bone morphogenetic protein (BMP9) in the patients with and without HPS	4 to 6 months after the study completion	the content and expression of BMP9 were determined by immunohistochemistry.

Trial Locations

Locations (1)

Department of Anesthesiology, Southwest Hospital Third Military Medical University; 🇨🇳 Chongqing, Chongqing, China